REGULATORY

National Institute of Public Health to Play Core Role in CEA Public Analysis Process

December 6, 2018
The Ministry of Health, Labor and Welfare (MHLW) on December 5 presented a specific set-up for performing public analyses under its envisioned full-scale cost-effective assessment (CEA) scheme, proposing to have its affiliate, the National Institute of Public Health (NIPH), play…

To read the full story

REGULATORY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…